Recombinant Factor VIII (Kogenate FS, BAY14-2222)
BiologicalHaemophilia A patients
NCT Number: NCT00874926
The aim of this international prospective, non-interventional post-marketing surveillance study is to obtain data on treatment procedures, long-term safety and efficacy and patient acceptance of KOGENATE Bayer in treatment of patients with haemophilia A under daily-life treatment conditions.
Looking for future studies?
Notify MeMale
Observational
Many Locations, Bahrain
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Haemophilia A patients
Time frame: After 12 months, after 24 months
Looking for future studies?
Notify MeBayer
Industry
Efficacy and Safety of Long-term Treatment With KOGENATE Bayer/FS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04805021
Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited
Nantes, France
View Trial DetailsNCT03588299
Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited
Little Rock, Arkansas, United States
View Trial DetailsNCT04293523
Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited
Brno, Czechia
View Trial DetailsNCT02941783
Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited
View Trial Details